Home › Prostate Cancer › NCT05882253
Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)
Recruiting
Validation, Calibration, and Translation of Restriction Spectrum Imaging Signal Maps to Enhance MRI Diagnostic Capabilities in Prostate Cancer
Who can join
All ages · Men
Full eligibility criteria
Inclusion Criteria: * Selected to undergo an MRI-fusion prostate needle biopsy of the prostate. * Able to provide informed consent Exclusion Criteria: * prior diagnosis of prostate cancer (Grade Group \>1) * metastatic prostate cancer * prior prostate cancer treatment * contraindication to prostate biopsy (e.g., on anticoagulation that cannot be safely discontinued) * inability to undergo MRI (e.g., too large to be accommodated in a scanner or with an implant incompatible with MRI). * Bilateral hip replacement * Unable to provide informed consent.
About the study
The researchers hope to learn if specific types of MRI software and techniques can help improve early prostate cancer detection at time of a MRI-guided prostate biopsy.
What is being tested
- Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI) (other)
Sponsor: University of California, San Diego · Participants: 225 · Started: Dec 4, 2023
Contact the study team
- Michael A Liss, MD, PhD · Phone: 858-249-1240
- Jessica Warbrick, ND · Phone: 858-249-1240
Official record on ClinicalTrials.gov — NCT05882253
Locations in the U.S.
| California | University of California, San Diego, La Jolla |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.